Unnamed Program

About NGGT

Next Generation Gene Therapeutics (NGGT) is a private, pre-revenue biotech developing gene therapies for rare and chronic diseases. The company leverages a dual-functional vector technology platform and operates a significant 90,000 sq. ft. cGMP manufacturing facility to support its pipeline. Its most advanced program, NGGT002 for Phenylketonuria (PKU), has reported positive data, positioning the company in the competitive gene therapy space with a global operational footprint in the US and China.

About DermaXon

DermaXon is a preclinical-stage drug discovery company utilizing a polypharmacology platform to develop novel small molecules for underserved conditions linked to the brain-skin axis, such as ichthyosis, Darier disease, pruritus, and pain. The company has secured multiple non-dilutive grants from NIH institutes and the Department of Defense, and has established a strategic partnership with AI company VantAI to accelerate two programs. While still pre-revenue, DermaXon's strategy combines targeted medicinal chemistry with academic collaborations to de-risk its pipeline aimed at genetic keratinization disorders and neuroinflammatory conditions.

About Accure Therapeutics

Accure Therapeutics is a private, pre-revenue biotech focused on high-need CNS diseases. The company leverages a target-driven approach based on recent advances in neurobiology and neurodegeneration. Its strategy involves maturing early-stage programs to a validation point attractive for partnership or acquisition by larger pharmaceutical companies, supported by a seasoned executive team with deep CNS and biotech experience.

About Verge Genomics

Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.

About Verge Genomics

Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.

About ReproNovo

ReproNovo is a private, clinical-stage biotech company targeting significant unmet needs in reproductive health, including male infertility and adenomyosis. The company's most advanced program, RPN-001 (leflutrozole), is in Phase 2 clinical trials in the U.S. and has received clinical trial approval in China. Backed by a seasoned leadership team and specialized international investors, ReproNovo is positioned to advance novel therapies in a large and growing global market.

About ReproNovo

ReproNovo is a private, clinical-stage biotech company targeting significant unmet needs in reproductive health, including male infertility and adenomyosis. The company's most advanced program, RPN-001 (leflutrozole), is in Phase 2 clinical trials in the U.S. and has received clinical trial approval in China. Backed by a seasoned leadership team and specialized international investors, ReproNovo is positioned to advance novel therapies in a large and growing global market.

Therapeutic Areas